Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LC-CTLs in Lung Cancer
NCT03353428Phase 2Withdrawn
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Nov 2017
- Primary completion
- Jan 2019
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of LC-CTLs in lung cancer, sponsored by Shenzhen Geno-Immune Medical Institute. Planned start Nov 2017; status: withdrawn.
02
Drugs
LC-CTLs
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT03353428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03353428.